Supplementary Figures S1-9 and Tables S1-3 from <i>NUAK2</i> Amplification Coupled with <i>PTEN</i> Deficiency Promotes Melanoma Development via CDK Activation

Supplementary Figures S1-9 and Tables S1-3. Supplementary Figure S1 - Effects of knockdown of NUAK2 on melanoma cells and specificity of the p-AKT antibody. Supplementary Figure S2 - Immunohistochemical analyses of p-Akt and NUAK2 expression in clinical specimens. Supplementary Figure S3 - Kaplan-Meier curves for overall survival of Acral and Non-CSD melanoma patients. Supplementary Figure S4 - Knockdown of NUAK2 induces apoptosis in SM2-1 melanoma cells. Supplementary Figure S5 - Immunohistochemistry showing the expression of p21 following inhibition of the PI3K pathway by LY294002. Supplementary Figure S6 - Schematic diagram of the regulation of the cell cycle machinery by NUAK2 and PI3K pathways. Supplementary Figure S7 - Knockdown of CDK2 by siCDK2 in C32 and mel18 melanoma cells. Supplementary Figure S8 - Immunohistochemical analyses of the expression of CDK2 in clinical specimens. Supplementary Figure S9 - Expression of NUAK2, PTEN, p-Akt, Akt and CDK2, and cell proliferation in various melanoma cell lines treated with Roscovitine. Supplementary Table S1 - Clinical parameters and expressions of CDK2, p-Akt and NUAK2 of 56 acral melanomas and 35 non-CSD melanomas with survival information. Supplementary Table S2 - Genomic status of NUAK2 and PTEN gene in each cell line. Supplementary Table S3 - Expression of p27 and CDK2 in primary melanomas with or without over-expression of NUAK2 and p-Akt.